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Medical Marijuana and Pharmacy Practice 
Abstract 
By way of the Compassionate Care Act of 2014, New York has become the 23rd state to create a process 
that will permit patients suffering from a “serious condition” to receive medical marijuana (or “cannabis”). 
Among those, it is the second state to prohibit the crude delivery system of smoking (Minnesota), and the 
third to involve pharmacists in the dispensing process (Connecticut and Minnesota). Because virtually 
every practicing pharmacist in New York will be caring for patients receiving some form of cannabinoid 
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Medical Marijuana and Pharmacy Practice 
Karl G. Williams, RPh, LLM, JD, Wegman’s School of Pharmacy/St. John’s Fisher 
By way of the Compassionate 
Care Act of 2014, New York has  
become the 23rd state to create a 
process that will permit paƟents 
suﬀering from a “serious condiƟon” 
to receive medical marijuana (or 
“cannabis”). Among those, it is the 
second state to prohibit the crude 
delivery system of smoking 
(Minnesota), and the third to  
involve pharmacists in the  
dispensing process (ConnecƟcut 
and Minnesota). Because virtually 
every pracƟcing pharmacist in New 
York will be caring for paƟents  
receiving some form of cannabinoid 
therapy, it is important to discuss 
the basic outlines established by 
the law and regulaƟons.   
The Act provided for the basic 
policies and framework for the  
paƟent care process, product  
development, and product  
distribuƟon. Also, the Act gave the 
Department of Health (“DoH”)  
authority to write regulaƟons to 
further clarify specific details that 
are necessary for safe, secure, and 
responsible implementaƟon of this 
therapy. The DoH regulaƟons were 
finalized and published on April 15, 
2015 and published in Title 10 of 
New York’s Code of Rules and  
RegulaƟons. 
PaƟents may receive medical 
cannabis if a properly qualified phy-
sician concludes that the paƟent 
will realize a “therapeuƟc or  
palliaƟve benefit” for one of ten 
listed serious condiƟons. The list 




?? Parkinson’s disease 
??MulƟple sclerosis 
?? Spinal cord damage exhibiƟng 
intractable spasƟcity 
?? Epilepsy 
?? Inflammatory bowel disease 
??Neuropathies 
??HunƟngton’s disease 
Also, cachexia, severe or chronic 
pain, severe nausea, seizures, and 
muscle spasms, associated with any 
of the listed diseases. In addiƟon, 
the Commissioner, in his discreƟon, 
may add Alzheimer’s disease,  
muscular dystrophy, dystonia, post-
traumaƟc stress disorder, and  
rheumatoid arthriƟs within eight-
een months of the eﬀecƟve date of 
the law; that is January 2016.  
As menƟoned, smoking is not 
an approved medicaƟon delivery 
system under the Compassionate 
Care Act. The regulaƟons specify 
that the following are permissible: 
liquid or oils for oromucosal use, 
metered oil/liquid for vaporizaƟon, 
and capsules for oral  
administraƟon. Edible food  
products are not currently  
permiƩed in the regulaƟons. The 
Commissioner may approve  
addiƟonal formulaƟons at a later 
Ɵme.  
A physician who treats one or 
more of these condiƟons, and has 
registered with DoH to provide this 
therapy, may issue a “cerƟficaƟon” 
for primary or adjuncƟve treatment 
if, in his or her “professional  
opinion”, the paƟent will benefit. 
NoƟce that the cerƟficaƟon is not a 
prescripƟon in the tradiƟonal 
sense. PrescripƟon has a discrete 
definiƟon under the Code of  
Federal regulaƟons, and incon-
sistent with its use in ordering a 
Schedule I controlled substance. It 
is perhaps beƩer to view the  
cerƟficaƟon as an alterna?ve to the 
prescripƟon. Like a prescripƟon, the 
pracƟƟoner is directed to consider 
the form of cannabis, route of  
administraƟon, parƟcular strain, 
variety, quanƟty, dosage, and any 
limitaƟons on therapy. Also, the 
cerƟfying physician (or a designee) 
is required to review the  
prescripƟon monitoring program 
(or “PMP”, as established in the 
iSTOP law) registry prior to  
cerƟficaƟon for the “purpose of 
reviewing a paƟent’s controlled 
substance history”.  
Once cerƟfied by the physician, 
paƟents must then submit an  
applicaƟon to the DoH for a registry 
ID card enabling the acquisiƟon, 
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lawful possession, and use of a 
specified product for a maximum 
30-day supply. Also, the law  
provides for registraƟon of 
“designated caregivers” who may 
assist paƟents in this process. This 
may include picking up the  
medicaƟon from the dispensary, 
assistance with dosing, and  
temporary possession as long as 
the caregiver has registered and 
has an oﬃcial ID card. The registry 
ID card expires one year from the 
date the cerƟficaƟon is signed by 
the physician unless the paƟent is 
terminally ill, in which case the  
physician may specify that  
cerƟficaƟon will terminate on the 
death of the paƟent. 
Medical cannabis will be  
supplied by “registered  
organizaƟons” that have been  
approved by the DoH. Each of five 
registered organizaƟons will be  
integrated (“seed-to-sale”) to  
culƟvate, formulate products, and 
dispense to registered paƟents or 
caregivers. Each “registered  
organizaƟon” is permiƩed to  
operate four dispensaries, located 
separately from the producƟon  
faciliƟes, in various locaƟons 
around the state. The dispensaries 
will be located in the following 
counƟes: Nassau, New York (2),  
Onondaga (3), Erie (2), Suﬀolk,  
Clinton, Monroe, Broome, Albany 
(3), Westchester (2), Queens,  
Ulster, and Bronx.  
On receipt of a proper registry 
ID card, dispensary personnel 
(unlike pharmacies) are required to 
check the PMP registry to ensure 
that the paƟent will not have more 
than a 30-day supply with a 7-day 
grace period. That is, the paƟent 
may receive a refill within seven 
days of the Ɵme the previous  
supply would be exhausted. This is 
the same standard followed by 
community pharmacists for  
controlled substances. In addiƟon, 
dispensary personnel will aƩach a 
paƟent-specific label to the  
unopened package that includes  
??Name and registry ID number 
of the paƟent (and designated 
caregiver, if any); 
?? CerƟfying physician; 
??Dispensing facility name,  
address, and phone number; 
??Dosing and administraƟon 
instrucƟons; 
??QuanƟty and date dispensed; 
and 
?? Any recommendaƟon or  
limitaƟon as to use of the 
medicaƟon. 
Also, at the Ɵme of dispensing, 
a safety insert shall be provided 
which will include informaƟon on 
administraƟon methods, potenƟal 
dangers associated with use, how 
to recognize problem usage and 
obtain appropriate treatment, and 
other relevant informaƟon. Finally, 
the dispensary is required to, within 
24 hours, report dispensed  
products to the DoH. This is similar 
to any controlled substance  
delivered to/for a paƟent in the 
pharmacy context. This step will 
provide the informaƟon that, 
among other things will populate 
the PMP. 
Impact on Pharmacy PracƟce 
Given the noted similariƟes to 
community pharmacies (and  
perhaps contrary to intuiƟon), it is 
important to state explicitly that 
dispensaries are not pharmacies. 
Unlike pharmacies that are  
regulated by the Department of 
EducaƟon, dispensaries are licensed 
and regulated by the Department 
of Health. An interesƟng provision 
in the law reads: “Medical  
marihuana shall not be deemed to 
be a “drug” for the purposes of  
arƟcle one hundred thirty-seven of 
the educaƟon law”. This would 
seem to limit regulaƟon by the 
Board of Pharmacy/Department of 
EducaƟon and cements DoH as the 
sole regulatory authority  
concerning the organizaƟon and 
products. Also, dispensaries are 
permiƩed to distribute only medical 
cannabis products and associated 
administraƟon devices, unless other 
products are specifically approved 
by the department. 
Dispensaries will be similar to 
pharmacies in many ways that are 
extremely important to the profes-
sion. Perhaps chief among those is 
that “dispensing faciliƟes shall not 
be open or in operaƟon unless an 
individual with an acƟve New York 
state pharmacist license…is on 
premises and directly supervising 
the acƟvity within the facility”. That 
(Con?nued on page 12) 
is, each dispensary will require a 
supervising pharmacist to ensure 
the integrity of the dispensing  
process and, presumably,  
management of the inventory. This 
language is general enough to imply 
the need for authority to control 
processes, because there will surely 
be accountability if something goes 
wrong. 
In addiƟon to the supervisory 
role, there is an implicit clinical role 
for the pharmacist provided in the 
regulaƟons. SecƟon 1004.21(d)  
provides that no employee shall 
“counsel…on the use, admin-
istraƟon of, and the risks…unless…a 
pharmacist…or under the direct 
supervision of…the pharmacist  
on-site in the dispensing facility.”   
The pharmacists must complete a 
four-hour training program ap-
proved by the commissioner.  Since 
the unprofessional conduct rules of 
the Board of Regents prohibit dele-
gaƟon of counseling to any unli-
censed person, counseling 
(properly) must be conducted by a 
pharmacist or an intern. Among 
other things this implies the 
maintenance of an accurate  
medicaƟon profile and counseling 
as provided for in the pharmacy 
regulaƟons.  
Liability 
The threat of legal risk at the 
hands of the federal government 
has been the subject of recent 
speculaƟon. Pharmacists may well 
recall the 2005 case of Gonzales v. 
Raisch where the US Supreme Court 
aﬃrmed the authority of the  
federal government to intervene 
into a state’s medical cannabis  
process, despite even the slimmest 
eﬀect on interstate commerce.  
Indeed, as clearly discussed in 
“Marijuana – Medical or??”, in the 
Fourth Quarter 2014 EdiƟon of the 
New York State Pharmacist, the  
federal government is currently  
exercising “enforcement  
discreƟon”. That is, the US  
Department of JusƟce has publicly 
stated that it will conƟnue in this 
policy as long as states making  
cannabis available to its ciƟzens 
exercise a high level of integrity in 
the process through “strict  
regulatory schemes”. Given New 
York’s highly regulated process, and 
given the emerging understanding 
of the importance of cannabis in 
paƟent care, federal liability has 
become extremely remote for New 
York’s pharmacists. 
Conclusions 
Pharmacists in clinical pracƟce 
in New York, regardless of the  
nature of the pracƟce, will be in a 
posiƟon to ensure that paƟents  
receiving medical cannabis therapy 
will receive opƟmal care. Indeed, 
there is a legal and moral 
obligaƟon to become ade-
quately prepared to pro-
vide this care. Most directly 
for those pracƟcing in a 
dispensary, it will be  
necessary to obtain a com-
plete paƟent medicaƟon 
profile for the purpose of 
prospecƟve review for con-
traindicaƟons, drug-drug 
interacƟons, and other po-
tenƟal drug therapy prob-
lems that may be addressed during 
counseling. Although it will not be 
dispensed in the hospital environ-
ment, community pracƟce, or long-
term care seƫng,  pharmacists will 
need to be aware of the fact of can-
nabinoid therapy for essenƟally the 
same reasons. Consistent with this, 
we will need to educate ourselves 
about cannabinoids to aﬀect  
paƟent care.       
New York Laws of 2014, Chapter 90. The de-
tails are contained in Ar?cle 33 of the Public 
Health Law at §§3360-3369-e. 
10 NYCRR, Chapter XIII, §§1004.1 through 
1004.23. 






10 NYCRR 1004.17, compare to 10 NYCRR 
80.73(f) PHL §3368(1)(b). 10 NYCRR §1004.12
(a).  8 NYCRR 29.7(a)(21)(ii)(b)(6). 8 NYCRR 
63.6(b)7,8. 545 US 1 (2005). 
McGuire, Don R, Volume 88, Issue 4, page 10, 
Fourth Quarter 2014. 
h?p://www.jus?ce.gov/opa/pr/jus?ce-
department-announces-update-marijuana-
enforcement-policy (accessed on 9/18/2015), 
announcing memo of Deputy A?orney Gen-
eral James M. Cole of August 29, 2013.  
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